PREFACE

1. 
   

   INTRODUCTION; Hellmann, K.
   1.1 Overview of the development of razoxane and dexrazoxane

   
   


2. 
   

   RAZOXANE
   2.1 Preclinical data - in vitro and in vivo; Hellmann, K.
   2.2 Modes of action, a brief summary; Rhomberg, W.
   2.3 Clinical studies of malignant tumors; Rhomberg, W.
   2.3.1 Razoxane as cytotoxic or cytostatic agent
   2.3.1.1 Leukaemias and lymphomas
   2.3.1.2 Solid tumors, single agent
   2.3.1.3 Solid tumors, multiagent therapy
   2.3.1.4 Adjuvant use of razoxane
   2.3.2 Razoxane as radiosensitizer
   2.3.2.1 Soft tissue- and osteosarcomas, chordomas
   2.3.2.2 Gastro-intestinal malignancies
   2.3.2.3 Lung cancer
   2.3.2.4 Other solid tumors
   2.3.3 Antimetastatic efficacy
   2.3.3.1 Preclinical evidence; Rhomberg, W.
   2.3.3.2 Metastasis and the entry of tumor cells into; the vasculature - prevention by razoxane; Hellmann, K.
   2.3.3.3 Clinical evidence; Rhomberg, W.
   2.3.4 Razoxane - a cytorallentaric drug; Hellmann, K.
   2.3.5 Toxicity; Rhomberg, W.
   2.4 Studies in non-malignant diseases
   2.4.1 Psoriasis and psoriatric arthropathy; Rhomberg, W.
   2.4.2 Crohn s disease and ulcerative colitis; Rhomberg, W.

   
   


3. 
   

   DEXRAZOXANE
   3.1 Preface
   3.2 The pharmacology of dexrazoxane; Hasinoff, B.B.
   3.3 Toxicology and pharmacokinetics; Hellmann, K.
   3.4 Identification of dexrazoxane as a cardioprotector; Herman, E.
   3.5 Clinical considerations
   3.5.1 Dexrazoxane as antitumour agent; Rhomberg, W.
   3.5.2 Protection against anthracyclin-induced cardiotoxicity:
   3.5.2.1 Two pivotal clinical studies. A report including pharmacology and safety issues; Rubens, R.
   3.5.2.2 Comments on study 88001 and 88006; Hellmann, K.
   3.5.2.3 Clinical studies on cardioprotection - an update; Jones, R.
   3.5.3 Non-cardioprotective efficacy; Langer, S.W. 3.5.4 Neurodegenerative diseases; Greig, N.

   
   


4. 
   

   SUMMARY and OUTLOOK; Hellmann, K. and Rhomberg, W.